Join to View Full Profile
160 East 34th Street10th FloorNew York, NY 10016
Phone+1 212-731-6366
Fax+1 212-731-5527
Dr. Wise is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- My expertise in the management of advanced urologic cancers incorporates the most recently developed imaging and therapeutic modalities and a broad array of targeted and immunotherapy-based clinical trials.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2013
OtherClass of 2011
Perelman School of Medicine at the University of PennsylvaniaClass of 2011
Certifications & Licensure
NY State Medical License 2013 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer Start of enrollment: 2022 Jun 27
Roles: Contact
Publications & Presentations
PubMed
- PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.Sungmin Woo, Anton S Becker, Doris Leithner, Charlotte Charbel, Marius E Mayerhoefer
European Radiology. 2025-03-20 - Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future.Matthew Siskin, Minas P Economides, David R Wise
Cancers. 2025-02-24 - In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.Justine Habault, Jennifer L Franco, Susan Ha, Jeffry A Schneider, Maud Voisin
The Prostate. 2025-02-16
Press Mentions
Prostate Cancer Cases Spike in This US State as Doctors Share Likely ReasonFebruary 6th, 2025- EU Thumbs up for Oral ADT for Prostate CancerFebruary 28th, 2022
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 MutationsSeptember 24th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
